Changing Lives of
Neuromuscular Patients
with Gene Therapy

Atamyo’s mission is to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseases

My goal is to be like everyone else and to have them forget my disability

Mandine

Read Patient Stories

About Atamyo

The name of the company is derived from two words: Atao which means “Always” or “Forever” in a Celtic language and myo which is the Greek root for everything muscle-related. This name conveys the spirit of the company in its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

Our Pipeline

At Atamyo, we use our expertise in gene therapy and muscular dystrophies to find new approaches for gene replacement.
Our goal is to design the best delivery system for a particular disorder, in order to decrease side effects and improve the restoring of a normal physiological function.

Diseases & Patient Communities

Limb girdle muscular dystrophies (LGMDs) are a group of rare genetic disorders characterized by a progressive dystrophic phenotype, mainly affecting the muscles of the shoulder and pelvic areas. Onset and severity of the symptoms are variable. Typical LGMD signs are difficulty in movements, wobbling gait and specific distribution of muscle atrophy.

Management

The management team of Atamyo is seasoned team of professionals with extensive experience in biotech and gene therapy.

Latest News

March 26, 2024

Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5

Atamyo has received approval to initiate a clinical trial of ATA-200 gene therapy in France and Italy ATA-200 is a single-injection gene therapy aimed to treat LGMD2C/R5 caused by mutations in the gamma–sarcoglycan gene The […]

October 27, 2023

First clinical results of ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), presented at ESGCT

ATA-100 is being evaluated in a multi-center phase 1b/2b “ATA-001-FKRP” study Completion of enrollment of the first dose cohort of 3 patients First results of cohort one presented at ESGCT in oral presentation Good clinical […]

September 29, 2023

Atamyo Therapeutics Announces participations in Conferences and Key Scientific Communications on its LGMD programs

Participation in Chardan’s 7th Genetic Medicines Conference Participation in Cell and Gene Therapy on the Mesa 2023 Meeting Five upcoming communications on LGMD programs at WMS congress, ESGCT annual meeting and 2023 International Limb-Girdle Muscular […]

September 19, 2023

ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, reaches key milestones with the filing of a clinical trial application in Europe and a non-dilutive financing from France 2030 program

A multicenter phase 1b study will evaluate safety, pharmacodynamic and efficacy of ATA-200 ATA-200 is the second Atamyo’s next generation gene replacement therapy entering the clinic ATA-200 is eligible to receive up to €8m ($8.6m) […]

September 06, 2023

IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA

LGMD 2I/R9 is a rare muscle dystrophy with no approved treatment ATA-100 is being evaluated in Europe in a multi-center phase 1b/2b Evry, France (September 5, 2023) – Atamyo Therapeutics, a biotechnology company focused on […]

September 26, 2022

Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial

• First patient dosed with ATA-100 gene replacement therapy for LGMD-R9• On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 Evry, France (September 26, 2022) – Atamyo Therapeutics, a biotechnology company focused […]